Table 2.
Univariate Cox regression analysis of risk factors for 30-day mortality in patients with vancomycin-resistant Enterococcus faecium bacteremia.
| Variable | Mortality group (n = 23) |
Survival group (n = 12) |
HR (95% CI) | P value |
|---|---|---|---|---|
| Age, years, median (IQR) | 49 (35.0) | 44 (31.5) | 1.01 (0.99–1.03) | 0.23 |
| Hematologic malignancy | 7 (30.4) | 2 (16.6) | 1.33 (0.54–3.29) | 0.52 |
| Solid malignancy | 4 (17.4) | 3 (25.0) | 0.64 (0.21–1.92) | 0.43 |
| Cirrhosis | 4 (17.4) | 0 (0) | 2.72 (0.91–8.15) | 0.07 |
| Diabetes mellitus | 2 (8.7) | 1 (8.3) | 1.10 (0.25–4.72) | 0.89 |
| Chronic obstructive pulmonar disease | 1 (4.3) | 0 (0) | 3.28 (0.41–25.9) | 0.25 |
| APACHE II score, median (IQR) | 26 (10) | 28 (4) | 0.97 (0.91–1.04) | 0.52 |
| Initial plasma CRP, mg/L, median (IQR) | 121.3 (92.2) | 222.2 (321.9) | 0.99 (0.99-1.00) | 0.21 |
| Initial serum albumin, g/L, median (IQR) | 2.3 (1.1) | 2.8 (0.8) | 0.74 (0.29–1.91) | 0.54 |
| Acute kidney injury | 11 (47.8) | 1 (8.3) | 3.65 (1.58–8.41) | 0.002 |
| ICU-acquired bacteremia | 17 (73.9) | 5 (41.6) | 1.84 (0.72–4.69) | 0.19 |
| Linezolid treatment | 15 (65.2) | 11 (91.6) | 0.09 (0.33–0.29) | <0.001 |
| Linezolid MIC, microgram/mL, mean ± SD | 0.95 ± 0.28 | 0.97 ± 0.22 | 0.78 (0.20–2.96) | 0.72 |
| Time to linezolid treatment, days, median (IQR) | 2.5 (1.0) | 4.0 (5.0) | 0.77 (0.57–1.05) | 0.11 |
| Duration of linezolid treatment, days, median (IQR) | 9.5 (6) | 10.5 (10) | 0.90 (0.80–1.02) | 0.11 |
Data presented as n (%) unless otherwise indicated. HR: hazard ratio; 95% CI: 95% confidence interval; IQR: interquartile range (P75–P25); CPR: C-reactive protein; ICU: intensive care unit; MIC: minimum inhibitory concentration; SD: standard deviation.